If you have been reading about retatrutide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Action Game – Grand Theft Auto: Vice City Adventure Game – The Legend of Zelda: The Wind Waker Animation or Intro – Soulcalibur II (Jame Chung Edition) Children's Game – EyeToy: Play Design – Grand Theft Auto: Vice City Game Boy Advance Game – Advance Wars 2: Black Hole Rising Game on Any Platform – The Year's Best Game – Call of Duty GameCube – Metroid Prime Mobile Game – Tony Hawk's Pro Skater Multiplayer – Battlefield 1942 Original Music – Harry Potter and the Chamber of Secrets PC – Grand Theft Auto: Vice City PS2 – Grand Theft Auto: Vice City Racing – Project Gotham Racing 2 Sound – Grand Theft Auto: Vice City Sports – FIFA Football 2004 Strategy – Advance Wars 2: Black Hole Rising Sunday Times Reader Award for Games – Grand Theft Auto: Vice City Technical Achievement – EyeToy: Play Xbox – Star Wars: Knights of the Old Republic Special Award (Games) – Chris Deering
=== Repression and counter-coups === It has been argued that failed coups might motivate a regime to reform and reduce repression. Such reforms are not obvious in the data, as of 2017. Coups that fail, or merely shuffle the leadership without changing the system, generally do not change the amount of repression (measured in government-sanctioned and pro-government killings). Research from 2016 suggests that increased repression and violence typically follow both successful and unsuccessful coup attempts. According to a 2019 study, coup attempts lead to a reduction in physical integrity rights. Coups that lead to democratization unsurprisingly reduce repression, and coups that bring in a new autocratic regime increase it. Post-Cold-War, post-coup autocracies seem to have become more repressive and post-coup democracies less repressive; the gap between them is therefore larger than it was during the Cold War. Averaging across democratic and non-democratic outcomes, most coups seem to tend to increase state repression, even coups against autocrats who were already quite repressive. The time interval in which violence is measured matters. The months after a bloodless coup can be bloody. The small sample size and high variability means that this conclusion again does not reach statistical significance, and a firm conclusion cannot be drawn. According to Naunihal Singh, author of Seizing Power: The Strategic Logic of Military Coups (2014), it is "fairly rare" for the incumbent government to violently purge the army after a failed coup.
The radical shift in the connotation of "genetic engineering" from an emphasis on the inherited characteristics of people to the commercial production of proteins and therapeutic drugs was nurtured by Joshua Lederberg. His broad concerns since the 1960s had been stimulated by enthusiasm for science and its potential medical benefits. Countering calls for strict regulation, he expressed a vision of potential utility. Against a belief that new techniques would entail unmentionable and uncontrollable consequences for humanity and the environment, a growing consensus on the economic value of recombinant DNA emerged.
The AlphaFold Protein Structure Database (AlphaFold DB) is a collaborative project with Google DeepMind to make predicted protein structures from the AlphaFold AI system freely available to the scientific community. The first release of the database was in 2021; as of 2024, AlphaFold DB provides access to over 214 million protein structures. National Center for Biotechnology Information (NCBI), United States National Library of Medicine National Institute of Genetics (DNA Data Bank of Japan) Swiss Institute of Bioinformatics (SIB: Expasy) Australia Bioinformatics Resource BIG Data Center (National Genomics Data Center), Beijing Institute of Genomics, Chinese Academy of Sciences Alternative splicing and transcript diversity database BioJS - open-source project for bioinformatics data on the web BioSamples European Molecular Biology Organization European Nucleotide Archive
First, a cell lysate is generated by glass beads beating, pressure homogenisation or chemical or physical lysis methods that do not denature the protein(s) of interest. (Optionally for targeted analysis) a protein of interest is purified out of this lysate by affinity methods based on intrinsically disordered tags or other suitable purification strategies, often involving several orthogonal chromatographic steps. This (total or purified) protein solution is aliquoted into several tubes of a PCR strip. All aliquots are exposed in parallel in a thermal gradient PCR cycler to different maximal temperatures in presence of the thermostable protease thermolysin (see figure). Automated temperature control is achieved in a thermal gradient cycler (commonly used for PCRs). Reaction products can be separated by SDS-PAGE or western blot. The protease thermolysin can be fully inactivated by EDTA. This feature of thermolysin makes FASTpp compatible with subsequent trypsin digestion e.g. for mass spectrometry.
Sources: en.wikipedia.org
Alyx Vance is a fictional character from Valve's Half-Life video game series. She is introduced as a non-playable, supporting character in Half-Life 2 (2004), accompanying the player's character, Gordon Freeman, throughout much of the game. She subsequently appears in a similar capacity in Half-Life 2: Episode One (2006) and Episode Two (2007), and as the titular protagonist of the VR game Half-Life: Alyx (2020). Alyx is portrayed as a young woman in her mid-twenties of Afro-Asian descent, and is a prominent figure in the human resistance against the rule of the alien empire called the Combine and their human representative, Dr. Wallace Breen. She is the daughter of resistance leader Dr. Eli Vance, and becomes a close friend and ally of Gordon. She received highly positive reviews from critics.
== Further reading == Kim ES, Deeks ED (September 2015). "Empagliflozin/Linagliptin: A Review in Type 2 Diabetes". Drugs. 75 (13): 1547–57. doi:10.1007/s40265-015-0457-z. PMID 26323340. S2CID 27675087.
Akan trade with European states began after contact with the Portuguese in the 15th century. European contact was by the Portuguese people, who came to the Gold Coast region in the 15th century to trade. The Portuguese then established the Portuguese Gold Coast (Costa do Ouro), focused on the availability of gold. The Portuguese built a trading lodge at a coastal settlement called Anomansah ("the perpetual drink"), which they renamed São Jorge da Mina. In 1481, King John II of Portugal commissioned Diogo de Azambuja to build Elmina Castle, which was completed in three years. By 1598, the Dutch had joined the Portuguese in the gold trade, establishing the Dutch Gold Coast (Nederlandse Bezittingen ter Kuste van Guinea – "Dutch properties at the Guinea coast") and building forts at Fort Komenda and Kormantsi. In 1617, the Dutch captured Elmina Castle from the Portuguese and Axim in 1642 (Fort St Anthony). European traders had joined in gold trading by the 17th century, including the Swedes, establishing the Swedish Gold Coast (Svenska Guldkusten), and Denmark–Norway, establishing the Danish Gold Coast (Danske Guldkyst or Dansk Guinea). European traders participated in the Atlantic slave trade in this area. More than 30 forts and castles were built by the merchants. The Germans established the Brandenburger Gold Coast or Groß Friedrichsburg. In 1874, Great Britain established control over some parts of the country, assigning these areas the status of the British Gold Coast. Military engagements occurred between the British colonial powers and Akan nation-states.
The white blood cell differential is a common blood test that is often ordered alongside a complete blood count. The test may be performed as part of a routine medical examination; to investigate certain symptoms, particularly those suggestive of infection or hematological disorders; or to monitor existing conditions, such as blood disorders and inflammatory diseases. Five types of white blood cells are normally found in blood: neutrophils, lymphocytes, monocytes, eosinophils and basophils. Marked shifts in the proportions of these cell types, as measured by the automated or manual differential, can indicate various health conditions. Additionally, cell types which do not normally occur in the blood, such as blast cells, can be identified by the manual differential. These cell types may be found in blood disorders and other pathological states. The manual differential can also identify changes in the appearance of white blood cells, such as reactive lymphocytes, or features such as toxic granulation and vacuolation in neutrophils. The results of the white blood cell differential are reported as percentages and absolute values. Absolute counts are usually reported in units of cells per microlitre (μL) or 109 cells per litre (L). The result are then compared against reference ranges, which are defined by individual laboratories and may vary due to different patient populations and testing methods. CBC and differential testing is usually performed on venous or capillary blood.
Sources: en.wikipedia.org
== Research == Lasofoxifene is under development by Sermonix Pharmaceuticals for the treatment of metastatic breast cancer and dyspareunia associated with vaginal atrophy in the United States and Europe. It is also being researched for the potential treatment of ovarian cancer. As of December 2017, lasofoxifene is in phase III clinical trials for breast cancer and phase II clinical studies for dyspareunia.
In nuclear physics, beta decay (β-decay) is a type of radioactive decay in which an atomic nucleus emits a beta particle (fast energetic electron or positron), transforming into an isobar of that nuclide. For example, beta decay of a neutron transforms it into a proton by the emission of an electron accompanied by an antineutrino; or, conversely a proton is converted into a neutron by the emission of a positron with a neutrino in what is called positron emission. Neither the beta particle nor its associated (anti-)neutrino exist within the nucleus prior to beta decay, but are created in the decay process. By this process, unstable atoms obtain a more stable ratio of protons to neutrons. The probability of a nuclide decaying due to beta and other forms of decay is determined by its nuclear binding energy. The binding energies of all existing nuclides form what is called the nuclear band or valley of stability. For either electron or positron emission to be energetically possible, the energy release or Q value must be positive. Beta decay is a consequence of the weak force, which is characterized by relatively long decay times. Nucleons are composed of up quarks and down quarks, and the weak force allows a quark to change its flavour by means of a virtual W boson leading to creation of an electron/antineutrino or positron/neutrino pair. For example, a neutron, composed of two down quarks and an up quark, decays to a proton composed of a down quark and two up quarks.
A 2017 study finds that countries' coup-proofing strategies are heavily influenced by other countries with similar histories. Coup-proofing is more likely in former French colonies. A 2018 study in the Journal of Peace Research found that leaders who survive coup attempts and respond by purging known and potential rivals are likely to have longer tenures as leaders. A 2019 study in Conflict Management and Peace Science found that personalist dictatorships are more likely to take coup-proofing measures than other authoritarian regimes; the authors argue that this is because "personalists are characterized by weak institutions and narrow support bases, a lack of unifying ideologies and informal links to the ruler". In their 2022 book Revolution and Dictatorship: The Violent Origins of Durable Authoritarianism, political scientists Steven Levitsky and Lucan Way found that political-military fusion, where the ruling party is highly interlinked with the military and created the administrative structures of the military from its inception, is extremely effective at preventing military coups. For example, the People's Liberation Army was created by the Chinese Communist Party during the Chinese Civil War, and never instigated a military coup even after large-scale policy failures (i.e. the Great Leap Forward) or the extreme political instability of the Cultural Revolution. Some scholars have posited that the recruitment of foreign legionnaires into national armies can reduce the probability of military coups.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.